Staphefekt

Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. The product is developed and produced by Dutch biotechnology company Micreos.[1][2]

The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.[3]

References

  1. ↑ Parmley, Stephen (2014-12-11). "Lysin in wait". SciBX: Science-Business eXchange. 7 (47). doi:10.1038/scibx.2014.1369.
  2. ↑ Herpers, Bjorn (2015-03-01). "Endolysins: redefining antibacterial therapy". Future Microbiology. 10 (3): 309–311. doi:10.2217/fmb.14.142. ISSN 1746-0913.
  3. ↑ Siew, Adeline (Apr 21, 2015). "Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability" – via www.pharmtech.com.

External links


This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.